The influence of PSA-RNA yield on the analysis of expressed prostatic secretions (EPS) for prostate cancer diagnosis

Canadian Journal of Urology

Volumn 20, Issue 1, 2013, Pages 6597-6602

  Whelan, Christopher ^a   Crocitto, Laura ^a   Kawachi, Mark ^a   Chan, Kevin ^a   Smith, David ^b   Wilson, Timothy ^a   Smith, Steven ^a,c  

^a Division of Urology and Urological Oncology   (United States)

^b Divison of Biostatistics   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Human PCA3; Human TMPRSS2 ERG fusion protein; Prostate; RNA

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE (NADP); MESSENGER RNA; ONCOPROTEIN; PROSTATE CANCER ANTIGEN 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TMPRSS2 ERG FUSION PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; GENETICS; HUMAN; MALE; MASSAGE; METABOLISM; MIDDLE AGED; PROSTATE; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; SECRETION (PROCESS); STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AREA UNDER CURVE; GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE (NADP+); HUMANS; LOGISTIC MODELS; MALE; MASSAGE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84884749767     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. SEER Cancer Statistics Review, 1975-2009. Available from URL: http://seer.cancer.gov/csr/1975_2009_pops09/index.html. Accessed February 5, 2013.
2. Toren P, Razik R, Trachtenberg J. Catastrophic sepsis and hemorrhage following transrectal ultrasound guided prostate biopsies. Can Urol Assoc J 2010;4(1):E12-E14.
3. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350(22):2239-2246.
4. Lin DW. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA. Urol Oncol 2009;27(3):315-321.
5. Reynolds MA, Kastury K, Groskopf J, Schalken JA, Rittenhouse H. Molecular markers for prostate cancer. Cancer Lett 2007;249(1):5-13.
6. Marks LS, Fradet Y, Deras IL et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69(3):532-535.
7. van Gils MP, Cornel EB, Hessels D et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 2007;67(8):881-887.
8. Groskopf J, Aubin SM, Deras IL et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52(6):1089-1095.
9. Laxman B, Tomlins SA, Mehra R et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8(10):885-888.
10. Crocitto LE, Korns D, Kretzner L et al. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 2004;64(4):821-825.
11. Clark JP, Munson KW, Gu JW et al. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. Clin Chem 2008;54(12):2007-2017.
12. Munson K, Clark J, Lamparska-Kupsik K, Smith SS. Biomarker target recovery in the methylation sensitive QPCR. Nucleic Acids Res 2007;35:2893-2903.
13. Hessels D, Klein Gunnewiek JM, van Oort I et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44(1):8-15;discussion 15-16.
14. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21(2):383-391.